AU2009309691B2 - Thienotriazolodiazepine derivatives active on apo A - Google Patents

Thienotriazolodiazepine derivatives active on apo A Download PDF

Info

Publication number
AU2009309691B2
AU2009309691B2 AU2009309691A AU2009309691A AU2009309691B2 AU 2009309691 B2 AU2009309691 B2 AU 2009309691B2 AU 2009309691 A AU2009309691 A AU 2009309691A AU 2009309691 A AU2009309691 A AU 2009309691A AU 2009309691 B2 AU2009309691 B2 AU 2009309691B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
och
meta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009309691A
Other languages
English (en)
Other versions
AU2009309691A1 (en
Inventor
Daniel Bellus
Herman Kempen
Barbara Staehelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circomed LLC
Original Assignee
Circomed LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circomed LLC filed Critical Circomed LLC
Publication of AU2009309691A1 publication Critical patent/AU2009309691A1/en
Application granted granted Critical
Publication of AU2009309691B2 publication Critical patent/AU2009309691B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2009309691A 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo A Ceased AU2009309691B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
EP08167982.1 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (2)

Publication Number Publication Date
AU2009309691A1 AU2009309691A1 (en) 2010-05-06
AU2009309691B2 true AU2009309691B2 (en) 2015-04-02

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009309691A Ceased AU2009309691B2 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo A

Country Status (11)

Country Link
US (1) US8569288B2 (enExample)
EP (1) EP2362876B1 (enExample)
JP (1) JP5490811B2 (enExample)
KR (1) KR101633742B1 (enExample)
CN (1) CN102292341B (enExample)
AU (1) AU2009309691B2 (enExample)
BR (1) BRPI0914406A2 (enExample)
CA (1) CA2741934C (enExample)
EA (1) EA018620B1 (enExample)
ES (1) ES2448567T3 (enExample)
WO (1) WO2010049466A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
CN103180318B (zh) * 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
CR20180336A (es) * 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet
CN121108105A (zh) * 2025-09-01 2025-12-12 江西帝劢药业有限公司 一种用连续湍流管式反应器制备2,5-二羟基-1,4-二噻烷的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3878833T2 (de) * 1987-05-28 1993-06-09 Yoshitomi Pharmaceutical Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels

Also Published As

Publication number Publication date
KR101633742B1 (ko) 2016-06-27
EA201100698A1 (ru) 2011-12-30
US20110230460A1 (en) 2011-09-22
BRPI0914406A2 (pt) 2015-10-20
AU2009309691A1 (en) 2010-05-06
CN102292341B (zh) 2014-09-10
WO2010049466A1 (en) 2010-05-06
EP2362876B1 (en) 2013-12-11
US8569288B2 (en) 2013-10-29
JP5490811B2 (ja) 2014-05-14
CA2741934A1 (en) 2010-05-06
KR20110091523A (ko) 2011-08-11
ES2448567T3 (es) 2014-03-14
EA018620B1 (ru) 2013-09-30
CN102292341A (zh) 2011-12-21
CA2741934C (en) 2016-09-13
JP2012506896A (ja) 2012-03-22
EP2362876A1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
CA2741934C (en) Thienotriazolodiazepine derivatives active on apo a
JP2756004B2 (ja) トリアゾロ―１，４―ジアゼピン系化合物
JP2002532501A (ja) キノリン誘導体
TWI531573B (zh) 新穎反轉模擬物之化合物及其用途
CN111138448A (zh) 抑制rip1激酶的杂环酰胺及其用途
CA2997382A1 (en) Substituted amino triazoles useful as human chitinase inhibitors
JPWO1993007129A1 (ja) 骨粗鬆症治療薬およびジアゼピン化合物
JP2001518895A (ja) ソマトスタチン作働薬
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
KR20040010762A (ko) 옥시토신 작용제
CN101541788A (zh) 作为激酶抑制剂的化合物和组合物
JP7523146B2 (ja) Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
KR970002640B1 (ko) 티에노디아제핀 화합물 및 그의 용도
JP2010229035A (ja) ピリドピリミジン−４−オン誘導体
JPH0565288A (ja) 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物
IE910770A1 (en) "New imidazo [1,2-c] quinazoline derivatives process for preparing these and pharmaceutical compositions containing them"
JP2005501858A (ja) オキシトシン作動薬としてのジアザシクロアルカン
JP2008509971A (ja) Ｅｇ５キネシンのインヒビターとして使用するためのベンゾチエノピリジン
CZ20022281A3 (cs) Substituované piperazinové deriváty jako inhibitory MTP, způsob jejich výroby a pouľití pro výrobu farmaceutického prostředku
HUT62007A (en) Process for producing thienotriazolo (or imidazolo) diazepine amides and pharmaceutical compositions comprising same
JP2006517530A (ja) オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
EP1885725B1 (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
JP3633008B2 (ja) チエノトリアゾロジアゼピン化合物
SK14992000A3 (sk) Spôsob inhibície mrpi

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired